{"url_path":"/sec/embc/8-k/2026-05-15/item-2-01","section_key":"item-2-01","section_title":"Item 2.01 Completion of Acquisition or Disposition of Assets.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1872789/0000947871-26-000546-index.html","accession_number":"0000947871-26-000546","cik":"0001872789","ticker":"EMBC","issuer_name":"Embecta Corp.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1872789/0000947871-26-000546-index.html","primary_entity_key":"0001872789","primary_entity_name":"Embecta Corp."},"word_count":257,"has_tables":true,"body_markdown":"**Item 2.01 Completion of Acquisition or Disposition of Assets.**\n\n \n\nOn May 15, 2026, Embecta Corp. (“embecta”) completed its previously\nannounced acquisition (the “Transaction”) of all of the issued share capital of Owen Mumford Holdings Limited (“Owen\nMumford”), a privately held, UK-based innovator and manufacturer of medical devices and drug-delivery technologies. The Transaction\nwas completed pursuant to an Agreement for the Sale and Purchase of Owen Mumford Holdings Limited (the “Purchase Agreement”),\ndated as of March 19, 2026, between embecta and Mark Owen, Adam Mumford (in his individual capacity and in his capacity as trustee of\nthe Mumford Family 2026 Trust), Anne Mumford (in her capacity as trustee of the Mumford Family 2026 Trust), Ellen Owen, Kim Priddis and\nNancy Millington.\n\n \n\nPursuant to the terms and conditions of the Purchase Agreement, embecta\nacquired Owen Mumford for an upfront cash payment of £100 million at closing (subject to customary adjustments, including for closing\nnet cash) and will pay up to an additional £50 million upon the achievement of certain commercial milestones related to sales of\nthe Aidaptus® next-generation auto-injector platform through the period ending June 30, 2029.\n\n \n\nThe foregoing description of the Purchase Agreement and the Transaction\ndoes not purport to be complete and is subject to, and qualified by reference in its entirety to the full text of the Purchase Agreement,\na copy of which was filed as Exhibit 2.1 to the Company’s Current Report on Form 8-K filed with the U.S. Securities and Exchange\nCommission (the “SEC”) on March 20, 2026 and is incorporated herein by reference."}